Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

	of entity	
VENU	S METALS CORPORATION LIMIT	ED
ABN 99 123	3 250 582	
We (t	he entity) give ASX the following	g information.
	t 1 - All issues ust complete the relevant sections (att	ach sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Listed options (Options)
2	Number of <sup>+</sup> securities issued or to be issued (if known) or maximum number which may be issued	13,982,620
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	The Options have an issue price of \$0.02 and are exercisable at \$0.20 expiring on 30 November 2019

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally Yes, the Options rank equally to the listed in all respects from the +issue options currently on issue date with an existing +class of quoted \*securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution interest payment 5 Issue price or consideration \$0.02 per Option 6 Purpose of the issue Funds raised will be used for: (If issued as consideration for the acquisition of assets, clearly Exploration at various gold targets at the identify those assets) Youanmi High Grade Gold Project Exploration at Youanmi Currans Cobalt Project Exploration for lithium at various other tenements General working capital purposes. 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 28 November 2016 resolution under rule 7.1A was passed 6c Number of \*securities issued [ Nil without security holder approval under rule 7.1 Number of \*securities issued 6d Nil with security holder approval under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	13,982,620	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements	Refer Annexure 1	
7	<sup>+</sup> Issue dates	20 November 2017	WARRANGE CONTRACTOR OF THE CON
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
8	Number and <sup>+</sup> class of all	Number 76,764,693	<sup>+</sup> Class Fully paid ordinary
	*securities quoted on ASX (including the *securities in section 2 if applicable)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	shares (VMC)

45,432,111

options

Quoted (VMCOA)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	<sup>+</sup> Class
1,500,000	Unlisted options exercisable at \$0.25 each on or before 30 November 2019 (vested 31 December 2016)
1,500,000	Unlisted options exercisable at \$0.25 each on or before 30 November 2019 (vesting 31 December 2017)
2,400,000	Unlisted options exercisable at \$0.30 each on or before 30 November 2019

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

### Part 2 - Pro rata issue

11 Is security holder approval required?

No

12 Is the issue renounceable or non-renounceable?

Non-renounceable

13 Ratio in which the \*securities will be offered

1 new Option for every 3 fully paid ordinary shares held on the Record Date

14 \*Class of \*securities to which the offer relates

**Listed Options** 

15 \*Record date to determine entitlements

7:00pm (Perth time) on 30 October 2017

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

No, all holdings are on one register.

17 Policy for deciding entitlements in relation to fractions

Fractional entitlements will be rounded up to the nearest whole number.

Appendix 3B Page 4

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	All countries other than Australia and NZ.
19	Closing date for receipt of acceptances or renunciations	5:00pm (Perth time) on 13 November 2017
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	2 November 2017
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	26 October 2017
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through	N/A

<sup>+</sup> See chapter 19 for defined terms.

	a broker?		
31	How do security holders sell part of their entitlements through a broker and accept for the balance?		
32	How do security holders dispose of their entitlements (except by sale through a broker)?		
33	*Issue date	20 November 2017	
	t 3 - Quotation of sec eed only complete this section if you are Type of *securities (tick one)	e applying for quotation of securities	
(a)	X *Securities described in Pa	rt i	
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entit	ties that have ticked box	34(a)	
Addit	ional securities forming a nev	v class of securities - N/A	
Tick to docum	indicate you are providing the informa ents	ntion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for the additional *securities		
Entities that have ticked box 34(b)			

<sup>+</sup> See chapter 19 for defined terms.

38	Number of *securities for which *quotation is sought	N/A	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction	N/A	
	period  (if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number N/A	<sup>+</sup> Class

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional \*securities is in ASX's absolute discretion. ASX may quote the \*securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.

<sup>+</sup> See chapter 19 for defined terms.

- There is no reason why those \*securities should not be granted \*quotation.
- An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before \*quotation of the \*securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director/Company secretary)	Date: 20 November 2017
Print name:	Dean Calder	

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	69,636,623	
<ul> <li>Add the following:</li> <li>Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	5,640 16,430 6,000	
<ul> <li>Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid *ordinary securities that became fully paid in that 12 month period</li> </ul>		
Note:  Include only ordinary securities here — other classes of equity securities cannot be added  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items		
<b>Subtract</b> the number of fully paid *ordinary securities cancelled during that 12 month period		
"A"	69,664,693	

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	10,449,703
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of +equity securities issued	300,000
or agreed to be issued in that 12 month period <i>not counting</i> those issued:	6,800,000
<ul> <li>Under an exception in rule 7.2</li> </ul>	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	7,100,000
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	10,449,703
Note: number must be same as shown in Step 2	
Subtract "C"	7,100,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	3,349,703

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	6,966,469	
Note: number must be same as shown in - Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	6,966,469	

Appendix 3B Page 12

<sup>+</sup> See chapter 19 for defined terms.